We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Aperiomics Launches Novel NGS Services

By LabMedica International staff writers
Posted on 17 Nov 2014
Aperiomics (Ashburn, VA, USA), founded in October 2013 to bring ground-breaking solutions that address disease challenges, has launched its first commercial services with its breakthrough “Absolute-NGS Pathogen Detection Platform.” The platform consists of a novel set of 3 new-generation sequencing (NGS) services that provide unique tools for more effective identification of known and unknown microorganisms, focusing on pathogens.

The Absolute-ID service identifies known pathogens in virtually any sample. More...
The Absolute-Discover service can discover new pathogens. The Absolute-Biome service is designed to identify all microorganisms present in a given sample – such microbiome studies can help understand the impact of disease, drugs, or environmental changes.

Aperiomics, named after the Latin "aperio" meaning to reveal, is rolling out this package to provide laboratories, public health care, and businesses with better tools for rapid pathogen identification. The unique service addresses the biggest challenge in applying NGS to real-world analysis – making sense of the massive amount of data spawned by NGS. Aperiomics’ innovative technology uses an unbiased sequencing and genomic analysis approach. With their novel combination of genomics and informatics, the company capitalizes on high-throughput NGS and advanced Bayesian statistics to produce faster and better results than other approaches.

According to Jeff Gallagher, CEO of Virginia Bio, “Much of the promise of the future of health care and biomedical research depends on innovative use of data analytics. Done right, this will yield speed, power, and insights well beyond forerunner products and services based solely in biology and chemistry. It will open up unimaginable new opportunities to create value for patients worldwide. Aperiomics is a case in point.”

Aperiomics CEO Crystal Icenhour, PhD, explains the importance of these services: “The majority of pathogens are currently never identified. Thus, the advantages of accurate determination can be measured with improvements in human health, significant cost savings, and reduced risks to public health.”

The technology behind these Aperiomics’ services is the result of collaboration by three co-founders: The company’s president, Keith A. Crandall, PhD and director of the Computational Biology Institute at George Washington University; Chief Technology Officer W. Evan Johnson, PhD and assistant professor of Medicine, Biostatistics, and Bioinformatics at Boston University School of Medicine; and Chief Science Officer Eduardo Castro-Nallar, PhD in Biological Sciences from George Washington University.

Aperiomics is seeking additional funding to expand operations and service capacity.

Related Links:

Aperiomics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The automated multiplex PCR assay runs on the BioFire Spotfire Vaginitis System, bringing molecular vaginitis testing to the point of care (Photo courtesy of bioMérieux)

Molecular Vaginitis Panel Gains FDA Clearance and CLIA Waiver for Point-of-Care Use

Vaginitis affects most women at least once in their lifetime and can cause painful, disruptive symptoms. Common causes include bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, reflecting... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: The CE-marked software IVD combines digital histopathology and clinicopathological data to generate a prognostic classification (Image Credit: Shutterstock)

Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer

In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.